Specialist Dr. Sahin Bedir

Specialist Dr. Sahin Bedir
Academic Title :
Specialist Dr.

Specialist Dr. Sahin Bedir is a MEDICAL ONCOLOGY specialist, providing services at ISU Medical Park Gaziosmanpasa.

Education and Academic Qualifications

  • Bachelor of Medicine, Faculty of Medicine - Trakya Üniversitesi, 2010
  • Specialization in Internal Medicine, Faculty of Medicine - Ege Üniversitesi, 2016
  • Specialization in Medical Oncology, Faculty of Medicine - İstanbul Üniversitesi Cerrahpaşa, 2022
  • Yalova Community Health Center (2010-2011)
  • Faculty of Medicine - Ege Üniversitesi, Resident Physician (2011-2016)
  • Karabük Training and Research Hospital (2017)
  • Faculty of Medicine - İstanbul Üniversitesi Cerrahpaşa, Sub-Specialty Resident Physician (2018-2022)
  • Bağcılar Training and Research Hospital, Medical Oncology Department, Internal Medicine Clinic (2022-2025)
  • Gaziosmanpaşa Hospital (2025 - Present)
  • Turkish Society of Medical Oncology
  • European Society for Medical Oncology (ESMO)
  • Sengul Samanci N, Cikman DI, Oruc K, Bedir S, Çelik E, Degerli E, Derin S, Demirelli FH, Özgüroğlu M. Immune-related adverse events associated with immune checkpoint inhibitors in patients with cancer. Tumori. 2021 Aug;107(4):304-310. doi: 10.1177/0300891620953468. Epub 2020 Sep 16. PMID: 32935638.
  • Sengul Samanci N, Çelik E, Bagcilar O, Erol BC, Bicki E, Oruc K, Bedir S, Degerli E, Derin S, Demirci NS, Demirelli FH. Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma. Melanoma Res. 2020 Oct;30(5):477-483. doi: 10.1097/CMR.0000000000000678. PMID: 32898388.
  • Celik E, Samanci NS, Karadag M, Demirci NS, Cikman DI, Derin S, Bedir S, Degerli E, Oruc K, Oztas NS, Demirelli FH. Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency. J Oncol Pharm Pract. 2021 Oct;27(7):1665-1673. doi: 10.1177/1078155220964895. Epub 2020 Oct 12. PMID: 33040673.
  • Değerli E, Şentürk Öztaş N, Alkan G, Bedir Ş, Derin S, Valıkhanova N, Saraç B, Kacar E, Demirci NS, Demirelli HF, Turna H. Relationship between pathological response and molecular subtypes in locally advanced breast cancer patients receiving neoadjuvant chemotherapy. J Chemother. 2023 Feb;35(1):29-38. doi:10.1080/1120009X.2022.2043514. Epub 2022 Feb 26. PMID: 35220928.
  • Değerli E, Derin S, Oruç K, Şengül Samancı N, Bedir Ş, Çelik E, Şentürk Öztaş N, Alkan G, Demirelli FH, Demirci NS. The demographic characteristics, prognosis, and relationship with cancer subtypes of hospitalized COVID-19 patients with malignancy: A single-center experience. J Med Virol. 2021 Oct;93(10):5839-5845. doi: 10.1002/jmv.27123. Epub 2021 Jun 12. PMID: 34081337; PMCID: PMC8242719.
Share :